RAP 3.57% 14.5¢ resapp health limited

Ann: Appendix 4D and Half Year Financial Report, page-7

  1. 2,044 Posts.
    lightbulb Created with Sketch. 42
    Going by recent studies results released by RAP from the Joondalup Hospital (JHC) in Sep 30th 2015 there were 120 new subjects, Mar 31st 2016 there were another 313 new subjects so I suspect there are now a total of 600 subjects which will be enough for a double blind and independent studies result release soon unless they need 1000+ subjects to be reached????

    "Australian Paediatric Clinical Study
    During the period, the Company continued to enrol children in its Australian paediatric clinical study. On 4 September 2017, ResApp announced it plans to broaden its paediatric clinical strategy by reconfiguring its Australian study to directly support European (CE) and Australian (TGA) regulatory filings. Since early 2017, the Australian paediatric study at Joondalup Hospital has been recruiting patients for double-blind prospective analysis with 230 patients recruited as at September 2017. To support regulatory submissions, a team of clinicians will perform adjudication and Curtin University health researchers will provide independent statistical analysis."
 
watchlist Created with Sketch. Add RAP (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.